How were Imugene's earnings last quarter?

Imugene Limited (ASX:IMU) released its quarterly earnings results on Thursday, February, 28th. The company reported $0.00 earnings per share (EPS) for the quarter.

What other stocks do shareholders of Imugene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Imugene investors own include Leap Therapeutics (LPTX) , LightPath Technologies (LPTH) , Jaguar Health (JAGX) , Groupon (GRPN) , Greenland Minerals (GGG) , Fortescue (FMG) , Diffusion Pharmaceuticals (DFFN) , Alumina (AWC) and Atossa Therapeutics (ATOS) .

ASX:IMU

Imugene (IMU) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free IMU Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 12.70 million shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: 3.03%
Price Target: N/A

Stock Analysis

Get Imugene alerts:

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Imugene Stock (ASX:IMU)

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

IMU Stock News Headlines

April 17, 2024 | bizjournals.com

Cell therapy firm acquires RTP manufacturing facility

April 16, 2024 | finance.yahoo.com

Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million

April 17, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 15, 2024 | markets.businessinsider.com

Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort

April 15, 2024 | finance.yahoo.com

Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort

April 15, 2024 | finance.yahoo.com

Imugene opens enrolment for Bile Tract Cancer expansion study

April 15, 2024 | msn.com

ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer’s

April 10, 2024 | finance.yahoo.com

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

April 17, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 9, 2024 | finanznachrichten.de

Imugene Limited: Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

April 9, 2024 | finance.yahoo.com

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

April 3, 2024 | msn.com

Guess which ASX 300 healthcare stock is storming higher on Chinese patent news

March 27, 2024 | finance.yahoo.com

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

March 15, 2024 | finance.yahoo.com

U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib

March 14, 2024 | finance.yahoo.com

Pendulum Therapeutics Introduces GLP-1 Probiotic

March 13, 2024 | finance.yahoo.com

UnityPoint in Des Moines releases renderings for mental health expansion

March 13, 2024 | finance.yahoo.com

Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System

March 12, 2024 | finance.yahoo.com

apoQlar enters into Collaboration with Mayo Clinic to Advance Patient Care with Extended Reality Technology

March 11, 2024 | finanznachrichten.de

Imugene Limited: Phase 1 onCARlytics solid tumour trial advances to combination arm treatment

March 11, 2024 | au.investing.com

FIVE at FIVE AU: Biggest fall on ASX in eight months

March 11, 2024 | au.investing.com

Imugene advances to combination dosing with Phase 1 onCARlytics solid tumour trial

March 10, 2024 | afr.com

Barrenjoey, Canaccord raising for Lake Resources; 39.1pc discount

February 22, 2024 | finance.yahoo.com

Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts

February 20, 2024 | msn.com

4 things a doctor who's written best-selling books about aging does daily in the hope of living longer

February 15, 2024 | proactiveinvestors.com

Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial

February 3, 2024 | msn.com

British Punjabi doctor leads ground-breaking international trial of bowel cancer vaccine

January 23, 2024 | finance.yahoo.com

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

See More Headlines

Receive IMU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imugene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2019
Today: 4/17/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:IMU
CUSIP: N/A
CIK: N/A
Web: www.imugene.com
Phone: 61 3 9824 5254
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-89,240,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -44.37%
Return on Assets: -26.15%

Debt

Debt-to-Equity Ratio: 3.33
Current Ratio: 5.73
Quick Ratio: 15.17

Sales & Book Value

Annual Sales: $15.03 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 3.75
Book Value: A$0.03 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 7,390,000,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 3.23

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Paul Edward-Alexander Hopper A.S.i.A (Age 68)
B.A (UNSW), FAICD, Executive Chairman
Comp: $316.1k
Ms. Leslie Chong
CEO, MD & Executive Director
Mr. Michael Tonroe ACA (Age 58)
B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD, CFO & Company Secretary
Comp: $424.28k
Dr. Nicholas J. Ede B.Sc.(Hons.)
Ph.D., Head of Corporate Development
Dr. Monil Shah M.B.A.
Pharm.D., Chief Business Officer
Dr. Bradley Glover Ph.D. (Age 55)
Chief Operating Officer
Ms. Ursula McCurry
Senior Vice President of Clinical Operations
Dr. John Byon
Senior Vice President of Clinical Development
Dr. Joseph Paul Woodard Jr.
M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders

IMU Stock Analysis - Frequently Asked Questions

How were Imugene's earnings last quarter?: Imugene Limited (ASX:IMU) released its quarterly earnings results on Thursday, February, 28th. The company reported $0.00 earnings per share (EPS) for the quarter.
What other stocks do shareholders of Imugene own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Imugene investors own include Leap Therapeutics (LPTX), LightPath Technologies (LPTH), Jaguar Health (JAGX), Groupon (GRPN), Greenland Minerals (GGG), Fortescue (FMG), Diffusion Pharmaceuticals (DFFN), Alumina (AWC) and Atossa Therapeutics (ATOS).

This page (ASX:IMU) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Imugene (IMU) Stock Price, News & Analysis

About Imugene Stock (ASX:IMU)

IMU Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

IMU Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info